This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of VR-CAP (Bortezomib and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the first-line treatment for patients with marginal zone lymphoma.
Marginal zone lymphoma (MZL) is a relatively common group of non-Hodgkin's lymphoma (NHL). The incidence rate is only inferior to diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL). Currently, NCCN guidelines recommend same treatment plan of FL like R-CHOP as the primary treatment for MZL. However, due to the great difference in cell origin and biological characteristics between FL and MZL, some patients can not achieve complete remission or relapse quickly after standard first-line treatment. A number of phase II clinical studies have evaluated the good efficacy of rituximab combined with chemotherapy in the treatment of MZL. Previous studies have shown that NF-B signaling pathway is in abnormal activation state in MZL. Bortezomib, a proteasome inhibitor targeting NF-B pathway, has a promising therapeutic prospect in relapsed and refractory MZL. The goal of our trial is to assess the efficacy and safety of VR-CAP (Bortezomib and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the first-line treatment for patients with marginal zone lymphoma.
|Condition||Marginal Zone Lymphoma, MALT Lymphoma|
|Treatment||Rituximab, cyclophosphamide, prednisone, Epirubicin, Bortezomib, Velcade|
|Clinical Study Identifier||NCT04433156|
|Sponsor||Henan Cancer Hospital|
|Last Modified on||23 August 2021|
You have contacted , on
Your message has been sent to the study team at ,
You are contacting
No annotations made yet
Congrats! You have your own personal workspace now.